CAR-T Therapy

DRUG12 trials

Conditions

ANCA Associated Vasculitis (AAV)Acute Lymphoblastic LeukemiaBurkitt LymphomaCAR-T Cell TherapyCD7+ T-ALL/LBLDiffuse Large B Cell Lymphoma RelapsedHigh Grade B-cell LymphomaLymphoma

Early Phase 1

Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma

NCT05979792

Zhao WeiliPeripheral T Cell Lymphoma

Start: 2023-09-01End: 2025-12-01Target: 35Updated: 2023-08-21

A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

RecruitingNCT07339332

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySystemic Lupus Erythematosus (SLE)

Start: 2026-01-16End: 2027-12-31Target: 12Updated: 2026-01-14

Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC

RecruitingNCT07355972

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySSc-Systemic Sclerosis

Start: 2026-01-16End: 2027-12-31Target: 12Updated: 2026-01-21

Phase 1

CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors

Not yet recruitingNCT06647329

Mingzhi ZhangCAR-T Cell Therapy, Lymphomas

Start: 2024-12-01End: 2026-12-31Target: 30Updated: 2024-10-17

CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.

RecruitingNCT06752785

Guangzhou Women and Children's Medical CenterAcute Lymphoblastic Leukemia

Start: 2024-10-01End: 2028-06-30Target: 10Updated: 2024-12-31

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

RecruitingNCT06822881

Beijing GoBroad HospitalSystemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)

Start: 2025-02-20End: 2026-12-31Target: 27Updated: 2026-03-10

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

RecruitingNCT07031713

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologySystemic Lupus Erythematosus (SLE)

Start: 2025-07-11End: 2027-03-31Target: 12Updated: 2025-11-24

The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

Not yet recruitingNCT07033299

Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyANCA Associated Vasculitis (AAV)

Start: 2025-07-01End: 2027-03-31Target: 12Updated: 2025-06-24

To Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT

RecruitingNCT07280494

Peking University People's HospitalCD7+ T-ALL/LBL

Start: 2025-08-18End: 2027-12-31Target: 18Updated: 2025-12-12

Phase 2

Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.

RecruitingNCT06218602

M.D. Anderson Cancer CenterLymphoma

Start: 2024-02-19End: 2028-08-01Target: 40Updated: 2026-08-17

Unknown Phase

Immunotherapy in Lymphoma

RecruitingNCT06796517

Sung-Soo ParkBurkitt Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, High Grade B-cell Lymphoma +2

Start: 2024-06-26End: 2025-12-31Target: 72Updated: 2025-01-28

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

RecruitingNCT07051850

Sung-Soo ParkMultiple Myeloma (MM), Multiple Myeloma, Relapsed

Start: 2025-07-14End: 2025-12-31Target: 174Updated: 2025-07-15

Related Papers

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood2024-10-2338 citations